ClearCut medical is a commercial-stage medical device company, selling the ClearCoast™ system in Europe as of 2023. The company developed the ClearCoast™ system, a novel portable MRI scanner for real-time intra-operative margin assessment of excised tissue during Breast Conserving Surgery (BCS), also known as lumpectomy. With the ClearCoast™ MRI system the surgeon can instantly identify, while at the operating room, marginal areas suspected to be malignant without special training for interpretation. As a result, there is no need to wait for pathologist assessment, and the surgeon can immediately proceed to remove the remaining malignant tissue at the margins without waiting days for a pathology report. Traditionally, the process to identify cancerous cells near the margins of a removed breast tumor involves waiting for a pathological examination, which can take several days to weeks after the surgery. Following pathological assessment, a second surgery is recommended in about 25% of cases when malignant cells are found at the margins, leading to significant costs, inefficiencies in the healthcare system, and most importantly, added emotional distress for patients. ClearCut medical are working towards an FDA approval aimed to enlarge their commercial footprint in the US as well the development of additional indications, for which the company required a new investment round.